読み込み中
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
前日終値
$19.45
+$0.78 · +4.18%
時間外
$19.45
$0.00 · 0.00%
10月9日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
日中レンジ
現在 $19.45
52週レンジ
現在 $19.45
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
34
割高
センチメント
69
強気
リスク
37
中程度のリスク
モメンタム
68
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
日中レンジ
現在 $19.45
52週レンジ
現在 $19.45
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | 3.31億 USD | 1.08億 USD | 4866.1万 USD |
| 売上原価 | 1118.3万 USD | — | — | — | — |
| 粗利益 | −1118.3万 USD | — | 3.31億 USD | 1.08億 USD | 4866.1万 USD |
| 研究開発 | 4.19億 USD | 3.96億 USD | 4.24億 USD | 3.59億 USD | 2.65億 USD |
| 販売・一般管理 | 9710.4万 USD | 1.05億 USD | 1.03億 USD | 9047.5万 USD | 7905.9万 USD |
| 営業費用 | 5.44億 USD | 4.87億 USD | 5.27億 USD | 4.49億 USD | 3.44億 USD |
| 受取利息 | 4290.4万 USD | 6463.6万 USD | 5150.5万 USD | 1477.4万 USD | 459.5万 USD |
| 減価償却費と償却費 | 1481.2万 USD | 899.2万 USD | 1672.6万 USD | 1038.3万 USD | 859.3万 USD |
| 営業利益 | −5.55億 USD | −4.87億 USD | −1.97億 USD | −3.41億 USD | −2.96億 USD |
| 純利益 | −5.13億 USD | −4.23億 USD | −1.45億 USD | −3.26億 USD | −2.91億 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$33.67
上昇余地（73.11%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1.02億0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB7370.42万0.04%1853億 USD0.03%$289.48+0.64%
iShares Russell 2000 ETFIWM7239.12万0.09%782.66億 USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI5918.24万0.59%98.74億 USD0.35%$153.77+3.00%
Vanguard Morningstar Small-Cap Growth ETFVBK4244.06万0.09%447億 USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF4157.23万0.04%954億 USD0.05%$235+0.80%
T. Rowe Capital Appreciation Equity ETFTCAF2546.02万0.28%90.1億 USD0.31%$43.59+0.90%
iShares Russell 2000 Value ETFIWN2425.46万0.18%138.48億 USD0.24%$210.87-0.04%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFT. Rowe Capital Appreciation Equity ETFTCAFiShares Russell 2000 Value ETFIWNAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
